Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial

BACKGROUND: Alcohol is the leading cause of liver-related mortality worldwide. The gut–liver axis is considered a key driver in alcohol-related liver disease. Rifaximin-α improves gut-barrier function and reduces systemic inflammation in patients with cirrhosis. We aimed to compare the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Israelsen, Mads, Madsen, Bjørn Stæhr, Torp, Nikolaj, Johansen, Stine, Hansen, Camilla Dalby, Detlefsen, Sönke, Andersen, Peter, Hansen, Johanne Kragh, Lindvig, Katrine Prier, Rasmussen, Ditlev Nytoft, Thorhauge, Katrine Holtz, Kjærgaard, Maria, Karsdal, Morten, Hansen, Torben, Arumugam, Manimozhiyan, Trebicka, Jonel, Thiele, Maja, Krag, Aleksander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172147/
https://www.ncbi.nlm.nih.gov/pubmed/36893774
http://dx.doi.org/10.1016/S2468-1253(23)00010-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172147/
https://www.ncbi.nlm.nih.gov/pubmed/36893774
http://dx.doi.org/10.1016/S2468-1253(23)00010-9

Ejemplares similares